ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

AEON AEON Biopharma Inc

1.58
0.14 (9.72%)
May 31 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 91,837
Bid Price
Ask Price
News (1)
Day High 1.6698

Low
1.26

52 Week Range

High
17.17

Day Low 1.44
Share Name Share Symbol Market Stock Type
AEON Biopharma Inc AEON AMEX Common Stock
  Price Change Price Change % Share Price Last Trade
0.14 9.72% 1.58 17:07:39
Open Price Low Price High Price Close Price Previous Close
1.44 1.44 1.6698 1.58 1.44
Trades Shares Traded VWAP Financial Volume Average Volume 52 Week Range
753 91,837 US$ 1.59 US$ 146,019 - 1.26 - 17.17
Last Trade Type Quantity Price Currency
19:00:00 1,497 US$ 1.58 USD

AEON Biopharma Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
59.08M 37.16M - 52.75M 24.05M 0.65 2.46
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

AEON Biopharma News

Date Time Source News Article
5/31/202415:03Edgar (US Regulatory)Form S-1/A - General form for registration of securities..
5/24/202419:02Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of..
5/16/202415:27Edgar (US Regulatory)Form 8-K - Current report
5/14/202415:07Edgar (US Regulatory)Form 8-K - Current report
5/14/202408:15Edgar (US Regulatory)Form ARS/A - Annual Report to Security Holders: [Amend]
5/14/202408:14Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting..
5/14/202408:05Edgar (US Regulatory)Form 10-K/A - Annual report [Section 13 and 15(d), not S-K..
11/22/202320:48Edgar (US Regulatory)Form S-1/A - General form for registration of securities..
11/13/202308:01Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]
11/13/202308:00Edgar (US Regulatory)Form 8-K - Current report
10/19/202315:23Edgar (US Regulatory)Form 8-K - Current report
10/02/202316:06Edgar (US Regulatory)Form 8-K - Current report
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No AEON Message Board. Create One! See More Posts on AEON Message Board See More Message Board Posts

Historical AEON Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week1.701.951.261.48173,043-0.12-7.06%
1 Month1.402.081.261.64161,0710.1812.86%
3 Months12.5017.171.266.10110,763-10.92-87.36%
6 Months5.6017.171.266.6962,565-4.02-71.79%
1 Year10.1417.171.266.4570,798-8.56-84.42%
3 Years10.1417.171.266.4570,798-8.56-84.42%
5 Years10.1417.171.266.4570,798-8.56-84.42%

AEON Biopharma Description

AEON Biopharma, Inc. is a bio-pharmaceutical company. The Company is focused on developing ABP-450 (prabotulinumtoxinA) injection for the treatment of debilitating medical conditions with an initial focus on the neurology and gastroenterology markets. ABP-450 contains a 900 kDa botulinum toxin type-A complex produced by the bacterium clostridium botulinum. The active part of the botulinum toxin is the 150 kDa component, and the remaining 750 kDa of the complex is made up of accessory proteins. When injected at therapeutic levels, ABP-450 blocks peripheral acetylcholine release at presynaptic cholinergic nerve terminals by cleaving SNAP-25, a protein integral to the docking and release of acetylcholine from vesicles situated within the nerve endings leading to denervation and relaxation of the muscle. It is also engaged in the Phase II clinical study of ABP-450 for the treatment of cervical dystonia. Cervical dystonia, also known as spasmodic torticollis, is a neurological condition.